Patients with pulmonary arterial hypertension related to congenital heart disease should be managed in specialized centers to avoid common pitfalls and provide state-of-the-art care with targeted therapies.
Answers are grounded in this paper and cite their sources.
Specialized PAH-CHD care with targeted therapies may improve outcomes; leaves open prospective validation before practice change.
Pulmonary arterial hypertension related to congenital heart disease (PAH-CHD) is a common type of pulmonary arterial hypertension (PAH). Despite this, little emphasis has been given to this group of patients until recently, when compared with idiopathic PAH. This is largely because of the complexity and the wide range of underlying cardiac anatomy and physiology, with a multitude of adaptive mechanisms not fully understood. Pulmonary arterial hypertension related to congenital heart disease is, therefore, best diagnosed and managed in centres specializing in both CHD and PAH, to avoid common pitfalls and old practices and to provide state-of-the-art care. We discuss the optimal management of PAH-CHD patients in a series of actions to be taken in order to optimize short- and long-term outcome, based on current knowledge of the condition and the advent of targeted advanced therapies.
No takes yet. Share an insight, caveat, or question.
Dimopoulos et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: